Prazosin for Military Combat-Related PTSD Nightmares: A Critical Review
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Military combat is a common trauma experience associated with posttraumatic stress disorder (PTSD). Trauma-related nightmares are a hallmark symptom of PTSD. They can be resistant to label-pharmacological PTSD treatment, and they are associated with a variety of adverse health outcomes. The purpose of this article is to review and evaluate prazosin therapy for combat-related PTSD nightmares. Consistent with available literature for all-causes PTSD nightmares, prazosin is an effective off-label option for combat-related PTSD nightmares. Future trials may further instruct use in specific combat-exposure profiles.
Posttraumatic stress disorder (PTSD) is a growing national health issue, characterized by an individual’s immediate response to a putative traumatic event, followed by a persistent triad of clustered neuropsychiatric disturbances that result in life-role impairment and/or clinically significant distress.1 The psychopathological impact of exposure to traumatic events has long been recognized, especially in the context of war.2 Descriptions of combat-related sequelae date back thousands of years.2 Although modern conflicts engendered their own unique labels for these difficulties, it was not until after the Vietnam War that PTSD came to be a defined condition in the Diagnostic and Statistical Manual of Mental Disorders, (DSM) III.2–4
Even though many United States citizens are exposed to at least one lifetime potentially traumatic event,2,5 relatively few (6%−8%) develop PTSD.2,4,6,7 Trauma exposure rates and subsequent PTSD rates in service members with combat experiences have been shown to be elevated relative to community rates.2,4,5,8 Although military combat is one of the most common exposures associated with PTSD in men,7 PTSD incidence is greater in women after combat involvement.9 A study involving Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) combat veterans revealed rates of exposure to life-threatening events ranging from 84%−95% and self-reported rates of PTSD ranging from 4%−20%.10 Increased rates of PTSD are associated with greater frequency and intensity of combat exposure.10–12 Published rates of combat-related PTSD may be an underestimate, considering findings obtained from soldiers via anonymous data collection.11
Trauma-related nightmares are sometimes referred to as the “hallmark” symptom of PTSD,13,14 with acute prevalence rates as high as 90%.14 They are a common stress-induced casualty experienced by OIF/OEF military personnel engaged in combat operations15 and are reported by approximately 50%−70%13,16 of combat veterans with PTSD. They are among the most common, distressing, and treatment-resistant symptoms of PTSD.13,14,17–19 They can also persist beyond resolution of PTSD.17 Although the temporal relationship between trauma exposure, sleep disruption, and emergent PTSD is an area of ongoing examination,16,19 the presence of nightmares before14 or after14,17 a traumatic experience is predictive of eventual onset of PTSD, as well as a variety of behavioral health conditions and symptoms, including suicidal behavior.14 Persistent PTSD nightmares can impair quality of life, disrupt sleep, and generate a positive feedback loop of further neuropsychiatric, functional, and quality-of-life impairment.16–18 Trauma nightmares and sleep disruptions likely interface to promote the emergence, maintenance, and treatment-resistant characteristics of PTSD.13,14,16,19
PTSD symptomatology is believed to be mediated by excessive noradrenergic tone. Serial ambulatory in-dwelling cerebrospinal fluid noradrenergic monitoring of veterans with combat-related PTSD have revealed persistently elevated levels of norepinephrine, which correlated positively with PTSD symptoms as measured by the total Clinician-Administered PTSD Scale (CAPS; r=0.82, p <0.005).20 Supporting neurobiological evidence underlying the proposed substrates and the mechanistic pathophysiology of PTSD nightmares have been previously reviewed and include functional imaging and polysomnography (PSG), as well as peripheral markers of elevated noradrenergic activity.13 The proposed evidentiary model involves final common-pathway imbalanced sleep architecture and fragmented REM sleep, hypothetically related to central adrenergic hyperactivity.13 Elevated adrenergic tone is proposed to be consequent of combined amygdalar overactivity and reduced inhibitory medial prefrontal cortical input.13
The current 2009 American Psychiatric Association Clinical Practice Guideline Watch commented that traditional first-line psychotropic management of PTSD with FDA-approved selective serotonin reuptake inhibitors (SSRIs) appears to be differentially less efficacious for military veterans with combat-related PTSD.21 SSRIs have been characterized as “ineffective” for PTSD nightmares.13 In contrast, prazosin therapy has been identified as a promising off-label augmenting agent to traditional antidepressant intervention for the management of combat-PTSD sleep disturbances, including nightmares.13,21 In a recent Department of Veterans Affairs review,22 prazosin was described as a proven effective treatment for (all-cause) PTSD nightmares.
Prazosin is a generically-available, FDA-approved antihypertensive agent. It is a lipophilic alpha1 adrenergic antagonist with central activity.23–25 Prazosin may normalize REM architecture in humans with PTSD25 via attenuation of overly-active central noradrenergic tone, which is hypothesized to be one of the putative key driving pathophysiological processes behind PTSD nightmares.13,14,16,23
Only one publication26 has specifically reviewed the potential utility of prazosin for all-cause PTSD nightmares since the current APA Guideline Watch. There have been three other interval reviews, including a systematic review and commissioned task force “Best Practice Guide,” examining prazosin for all-cause nightmares,17,27 as well as an invited review of pharmacologic and non-pharmacological interventions for PTSD sleep disruptions, including nightmares.19 Although these reviews concluded that evidence supports the use of prazosin to treat nightmares, they all noted limitations with the currently available evidence-base. We are not aware of any critical reviews specifically examining the efficacy of prazosin therapy for combat-related PTSD nightmares. The purpose of this study is to systematically review the off-label use of prazosin for the management of combat-related PTSD nightmares.
Methods
Relevant articles published between 1996 and January 2013 were identified by use of MEDLINE. The following four primary search terms were used: 1) prazosin; 2) Minipress (then adding “or” prazosin from the populated list); 3) posttraumatic stress disorder (then adding “or” stress disorders, posttraumatic, from the populated list); and 4) nightmares (then adding “or” dreams from the populated list). Search terms #3 and #4 were combined, and that combination was then combined separately with search terms 1) prazosin and 2) Minipress. The primary search was augmented with an abstract search of the Military Health Research Forum (http://cdmrp.army.mil/default.shtml) peer-reviewed medical research programs, using “PTSD treatment” as our search term.
Inclusion criteria consisted of military veteran cohort or retrospective trials that examined the effect of prazosin on combat-related PTSD nightmares as a primary outcome measure. We excluded non-English articles, case series with fewer than five subjects, and any article where the majority of subjects did not have combat-related nightmares. For the purposes of this review, "majority" was defined a priori as >50% of subjects. Detected abstracts were reviewed independently by the authors to determine inclusion eligibility. Disagreements were resolved via consensus conference.
Each included study was reviewed by the authors and independently classified according to a modified grading system previously adapted and utilized by Warden et al.’s Neurobehavioral Guidelines Working Group.28 Each study was graded from Class I to Class III, with Class I status reserved for well-designed, double-blind, placebo-controlled trials with comparable validated primary outcome measures and reasonable subject recruitment of a representative population (Table 1). A consensus conference was held to ensure grading agreement among the authors.
| Class I | These are well-designed and conducted prospective, randomized, controlled trials (RCT) that use comparable validated primary outcome measures in a representative population. However, some may be downgraded because of poor design, insufficient patient numbers (N <20), or other methodological inadequacies. |
|---|---|
| Class II | These are well-designed and conducted clinical studies in which data are collected prospectively, or via retrospective analysis based on clearly reliable data. Types of studies so classified include: observational studies, cohort studies, prevalence studies, and case-control studies. As mentioned above, Class I design studies may be downgraded to Class II evidence because of methodological flaws. |
| Class III | Most studies are based on retrospectively-collected data. Evidence used in this class indicates well-designed and conducted clinical series, databases, or registries, case reviews, and case reports. Class I and II design studies may be downgraded to Class III evidence because of methodological flaws. As mentioned above, although a Class I study by design, an RCT could be downgraded by raters to Class II or Class III evidence or even be judged unusable, based upon the degree of methodological flaws. |
Results
Using our search methods, we identified 312 abstracts, which resulted in seven studies that met criteria for review. Six were prospective trials. These included three open-label15,29,30 and three randomized, placebo-controlled trials (RCTs), of which, two were parallel18,31 and one was a crossover trial.24 One RCT was a comparison trial.31 We identified one Class I,18 four Class II,24,30–32) and two Class III15,29 studies (Table 2). Six of the seven studies showed positive results for prazosin.15,18,24,29,30,32
| Reference and Evidence Class | Study Design | Demographic and Select Exclusionary Data | Entry Combat, Trauma, and Nightmare Data | Primary Outcome Measures | Primary Outcome Results |
|---|---|---|---|---|---|
| Randomized Controlled Trials; N=3 | |||||
| Class I evidence: Raskind et al., 200718 | Randomized, double-blind, placebo-controlled trial | N=40 | Veterans: 100% | CAPS B2 item | Mean nightly prazosin 13 (SD: 3) mg as compared with placebo improved |
| Parallel design | Age: 56 (SD: 9) years | Conflict: WWII to Gulf War I (80% Vietnam War) | PSQI | CAPS B2: 3.3 versus 0.9 (effect size: 0.94; p=0.02) | |
| 8-week duration | Male: 95% | Combat exposure: 77.5% | CGI-C | PSQI: 3.8 versus 0.08 (effect size: 1; p=0.008) | |
| Race: 65% White | CES: 9 | All measured pretreatment, Week 4, and posttreatment | Final CGI-C: 2.41 versus placebo 3.65 (effect size: 1.08; p=0.002) | ||
| Active SUD excluded | PTSD: 100% (DSM-IV) | ||||
| Total CAPS: 70 (SD: 20) | |||||
| CAPS B2: ≥5 (6.1 to 6.5; SD: 1) | |||||
| Class II evidence: Raskind et al., 200324 | Randomized, double-blind, placebo-controlled trial | N=10 | Veterans: 100% | CAPS B2 item | Mean nightly prazosin 9.5 (SD: 0.5) mg as compared with placebo improved |
| Cross-over design | Age: 53 (SD: 3) years | Conflict: 100% Vietnam War | CAPS D1 item | CAPS B2: 3.3 versus placebo 0.4 (effect size: 1.9; p <0.001) | |
| 20-week duration (9-week prazosin exposure) with crossover at Week 10 | Male: 100% | Combat Exposure: 100% | CGI-C | CAPS D1: 3.4 versus placebo by 0.2 (effect size: 1.6; p <0.01) | |
| Race: Unreported | CES: not used | CAPS B2 and D1 items measured pre- to post-treatment and CGI-C measured post-treatment only | Final CGI-C: 2 versus placebo 4.5 (effect size: 1.4; p <0.01) | ||
| Active SUD excluded | PTSD: 100% (DSM-IV) | ||||
| Total CAPS: 79 (SD: 17) in prazosin group to 84 (SD: 18) in placebo group | |||||
| CAPS B2: ≥6 (mean: 7; SD: 0.9 in both groups) | |||||
| Class II evidence: Germain et al., 201231 | Randomized, double-blind, placebo-controlled comparison trial of BSI versus prazosin | N=50 | Veterans: 100% | Sleep items | Active treatment (including mean nightly prazosin 8.9 (SD: 5.7) mg) did not significantly improve nightmare frequency (PghSD) |
| Parallel design | Age: 40.9 (SD: 13.2) years | Conflict: mixed (48% OIF/OEF) | ISI, PSQI, PSQI-A, PghSD (included measure of nightmare frequency) | Active treatment improved ISI (p <0.01) as compared with placebo | |
| 8-week duration | Male: 90%; | Combat exposure: 82% | Primary Global Outcomes: Patient and Clinician | Active treatment did not improve any other sleep or global primary outcomes | |
| Race: 82% White | CES: 14.9 (SD: 11.8) | ||||
| Active SUD excluded | PTSD: 58% (DSM-IV) | Sleep and global measures obtained at baseline, posttreatment, and 4 months; Global also obtained weekly | |||
| No significant between-group demographic differences | Total CAPS: 40 (SD: 22.4) | ||||
| CAPS B2: ≥3 | |||||
| Open-Label Trials; N=3 | |||||
| Class II evidence: Peskind et al., 200330 | Open-label series; | N=9 | Veterans: 89% | CAPS B2 item | Mean nightly prazosin 2.3 (SD: 0.7) mg as compared with baseline improved: |
| 8-week duration | Age: 76 (SD: 2) years | Conflict: 50% Korean, 50% WWII | CGI-C | CAPS B2: 5.7 to 0.9 (paired t-test=9.8; p <0.0001) | |
| Male: 100%; | Combat exposure: 89% | CAPS B2 item measured pre- to post-treatment, and CGI-C measured post-treatment only | Posttreatment CGI-C: 1.8 (SD: 0.7) | ||
| Race: Unreported | CES: not used | ||||
| Active SUD excluded | PTSD: 100% (DSM-IV) | ||||
| Total CAPS: Unreported | |||||
| CAPS B2: ≥5 (mean: 6.6; SD: 1.1) | |||||
| Class III evidence: Calohan et al., 201015 | Open-label series | N=13 | Veterans: 100% | CAPS B2 item | Mean nightly prazosin 4.1 (SD: 2.2) mg as compared with baseline improved |
| Non-fixed study duration, variable (days to weeks) duration of prazosin exposure | Age: 26.7 years | Conflict: 100% active OIF operations | CAPS D1 item | CAPS B2: 4.1 to 2.9 (paired t-test=4.8; p <0.001) | |
| Sex: 85% men | Combat exposure: 92% | CGI-C | CAPS D1: 3 to 3.7 (paired t-test=6; p <0.001) | ||
| Race: Unreported | CES: Not used | CAPS B2 and D1 items measured pre- to post-treatment and CGI-C measured post-treatment only | Posttreatment CGI-C: 1.9 (SD: 1) | ||
| Active SUD: unreported | PTSD: Unspecified mixture of DSM-IV PTSD and ASD | ||||
| Total CAPS: Unreported | |||||
| CAPS B2: 7 (SD: 0.7) | |||||
| Class III evidence: Thompson, et al., 200829 | Open-label series | N=22 | Veterans: 100% | CAPS B2 item | Mean nightly prazosin 9.6±6 mg as compared with baseline improved: |
| Non-fixed study duration, weeks of prazosin exposure | Age: Unreported | Conflict: Unreported | Modified CAPS B2 item (NNDA) | CAPS B2: 1.4 to 2.2 (p <0.05) | |
| Race: Unreported | Combat exposure: 77% | CAPS D1 item | NNDA: 3.1 to 2.1 (p <0.01) | ||
| Active SUD excluded | CES: not used | CGI-C | CAPS D1: 3.1 to 4.1 (p <0.01) | ||
| PTSD: 100% (DSM-IV) | Posttreatment CGI-C: 2.7 (SD: 1) | ||||
| Total CAPS: Unreported; | CAPS outcomes measured pre- to post-treatment, and CGI-C measured post-treatment only | ||||
| CAPS B2: 3.6 (SD: 2.6) | |||||
| Retrospective Chart Review; N=1 | |||||
| Class II evidence: Raskind et al., 200232 | Retrospective chart review; 8-week duration | N=59 | Veterans: 100% | CAPS B2 item | Mean nightly prazosin 6.3 (SD: 0.8) mg as compared with baseline improved |
| Age 51 (SD: 1.2) years; Men: 100% | Conflict: unspecified mix of Vietnam/Gulf War | CGI-C | CAPS B2: 2.9 to 4.2 (paired t-test=9.1; p <0.0001) | ||
| Race: Unreported | Combat exposure: 100% | CAPS B2 measured pre- to post-treatment, and CGI-C measured post-treatment only | Posttreatment CGI-C: 2.9 (SD: 0.1) | ||
| Active SUD excluded | CES: not used | ||||
| PTSD: 100% (DSM-IV) | |||||
| Total CAPS: unreported | |||||
| CAPS B2: ≥5 (mean: 7.1; SD: 0.2) | |||||
SD: standard deviation; ASD: Acute Stress Disorder; BSI: Behavioral Sleep Intervention; CAPS: Clinician-Administered Posttraumatic Stress Disorder Scale; CES: Combat Exposure Scale; CGI–C: Clinical Global Impression–Change; ISI: Insomnia Severity Index; NNDA: Non-Nightmare Distressed Awakenings; PghSD: Pittsburgh Sleep Diary; PSQI: Pittsburgh Sleep Quality Index; PSQI-A: PSQI Addendum for PTSD; SUD: Substance Use Disorder.
All seven studies examined the impact of prazosin augmentation on predominately combat-related PTSD nightmares as a primary outcome. Item B2, “recurrent distressing dreams of the event,” from the Clinician-Administered PTSD Scale for DSM-IV (CAPS),33 was the most common primary outcome measure to evaluate this effect. It was used in six of the seven studies.15,18,24,29,30,32 This item measures both the frequency and intensity of nightmares by use of a 5-point dimensional scale, from 0 to 4, for each variable over a specified duration of time33 (Table 3). The item score is reported as a combination total score of both variables, ranging from 0 to 8, with higher scores indicating greater nightmare pathology. A frequency score of ≥1 combined with an intensity score of ≥2, for a combined score of ≥3 is the typical dichotomous definition of a PTSD “symptom” on the CAPS.34 All seven studies reported a minimum baseline CAPS B2 total score of at least 3.
| Clinician-Administered PTSD Scale (CAPS) B2 Item30 | |
|---|---|
| Frequency | Intensity |
| Have you ever had unpleasant dreams about the event(s)? How often in the past month? | At their worst, how much distress or discomfort did these dreams cause you? Did these dreams wake you up? [If yes, ask:] What were you feeling or doing when you awoke? How long does it usually take you to get back to sleep? [Listen for report of panic symptoms, yelling, posturing.] |
| 0: Never | 0: None |
| 1: Once or twice | 1: Mild, minimal distress, did not awaken |
| 2: Once or twice a week | 2: Moderate, awoke in distress but readily returned to sleep |
| 3: Several times a week | 3: Severe, considerable distress, difficulty returning to sleep |
| 4: Nightly or almost every night | 4: Extreme, overwhelming, or incapacitating distress, could not return to sleep |
CGI–C:32 1: markedly improved; 2: moderately improved; 3: minimally improved; 4: unchanged; 5: minimally worse; 6: moderately worse; 7: markedly worse.
The Clinical Global Impression of Change Scale (CGI-C) was used in all seven studies. It is a widely-used, brief, clinician-administered continuous measure of global clinical change.35 It is a 7-point scale, ranging from 1 to 7, with lower scores (<4) representative of greater clinical improvement and higher scores (≥4) indicative of increasing clinical difficulties (Table 3).
Across all studies, 185 of 210 enrolled participants (88%) were reported as study completers. Comparison of study methodology revealed that most subjects were evaluated in ambulatory settings; they were predominantly middle-aged men (172 of 181 reported subjects, or 95%) from a variety of armed conflicts dating back from World War II veterans (N=4) through ongoing operations in Iraq/Afghanistan (OIF/OEF; N=24), and most were veterans of the Vietnam War (N>48). The majority of subjects had been exposed to combat (178 of 203, or 88%). Two trials18,31 quantified combat exposure via the Combat Exposure Scale (CES),33 with mean entry scores ranging from 9 (“light-to-moderate”) to approximately 18 (“moderate”) combat exposure. Whereas most studies examined “chronic” DSM-IV PTSD,24,29,30,32 one involved an unreported mixture of PTSD and Acute Stress Disorder related to active (OIF) combat operations.15 Although two did not specify the PTSD duration, they supplemented the DSM-IV PTSD diagnosis with a supporting continuous CAPS total score.18,31
Randomized Clinical Trials
Two of the three RCTs were positive, including one Class I study18 and one Class II study.24 The most recent study31 was negative and was graded as Class II evidence.
Two of the RCTs used comparable methods.18,24 These two studies enrolled a combined total of 50 subjects, of which 40 were analyzed completers. These studies involved a preponderance of middle-aged Vietnam veterans, with mostly (82%) combat-related, chronic DSM-IV PTSD nightmares as defined by a pretreatment mean CAPS B2 score of 5 or 6. Both evaluated the impact of prazosin augmentation relative to continued baseline combined psychotropic and therapy interventions. Active substance misuse was excluded. Eight-to-nine weeks of 9.5 mg24-to-13 mg18 of nightly prazosin significantly improved nightmares (effect sizes: 1.9–0.94) and global clinical/functional status (effect sizes: 1.4–1.08, respectively). There was no significant outcome difference between those using and those not using concurrent psychotropics.18 The primary measure of sleep quality (PSQI) was also significantly improved.18 Statistically significant reduction in nightmares did not occur until Week 8.18 Specific secondary measures of military combat nightmare frequency and content significantly improved by Week 8.18 Although dizziness occurred in some subjects, there were no statistically significant changes in blood pressure.18 Crossover design24 to placebo resulted in rapid return of nightmares in five subjects, which again resolved with requested open-label conversion back to prazosin in four of these subjects.
The third RCT was the most recent and the only negative study detected by the review.31 It was a placebo-controlled (N=15), randomized, comparison parallel 8-week trial of prazosin (N=18) versus behavioral sleep intervention (BSI; N=17) for sleep disturbances in a total of 50 enrolled adult (primarily OIF/OEF) veterans. BSI was defined as Masters-level, licensed-therapist delivery of manualized education/behavioral techniques, including image rehearsal therapy, stimulus control, and sleep restriction. Mean prazosin dose was approximately 9 mg per evening. Active substance misuse was excluded. PTSD was determined categorically (DSM-IV) as well as continuously measured via the CAPS total score; 58% of subjects met DSM-IV criteria, and 42% endorsed “subthreshold” PTSD symptoms. The mean sample CAPS total score for current PTSD difficulties was 40, which fell short of available empirically-derived categorical cutoffs for PTSD diagnosis.34 All subjects endorsed baseline clinically-meaningful distressing dreams, as evidenced by a CAPS B2 score of at least 3. Combat exposure was reported in 82% of the analyzed sample and measured via the CES with means ranging from approximately 10 to 18 across the three groups that trended (p=0.09) toward significant difference. Similar to previous RCTs, baseline psychotropics were continued unchanged. However, unlike previous RCTs, this study did not use a comparable primary outcome measure of nightmares. Rather, subject recall of distressing dream frequency upon waking was evaluated as part of a primary-outcome sleep diary. As such, nightmare intensity was not prospectively measured. Although both prazosin and BSI significantly improved insomnia, neither significantly reduced the frequency of nightmares. Multiple potential explanations for this unexpected negative finding were offered, including low baseline frequency of nightmares. Specifically, the mean baseline nightmare frequency across the three groups ranged from 0.09 to 1 nightmare per night. Overall global status as measured by the primary outcome CGI did not significantly improve in either treatment group. No significant differences were noted between active treatment and placebo as measured by the Asberg Side Effect Scale, and there were no significant changes in blood pressure with prazosin.
Open-Label Trials
Three open-label series were found. All were positive, including one Class II30 and two Class III studies.15,29
The three open-label series15,29,30 described 44 total subjects. All studies utilized the same primary outcome nightmare (CAPS B2) and global status (CGI-C) measures. They involved both young-adult OIF active combatants15 and geriatric veterans from a variety of remote conflicts.30 One series did not report comparable demographic data.29 Two studies involved chronic DSM-IV PTSD,29,30 and one (N=13) included an unspecified mixture of DSM-IV PTSD and Acute Stress Disorder.15 Collectively and individually, the studies included a preponderance of combat-exposed participants, ranging from 77% to 92% of the samples. Baseline trauma nightmare pathology as measured by the CAPS B2 ranged from 3.6 to 7, which was representative of threshold-symptomatic to severe and frequent nightmares, respectively. All series described the impact of prazosin augmentation relative to continued baseline psychotropics15,30 or combined psychotropic and non-cognitive therapy intervention.29 Two studies included comorbid medical and mental health conditions29,30 notable for medically frail geriatric subjects30 whereas the third study15 did not report comorbidity. Active substance misuse was excluded where reported.29,30 Mean prazosin dosing ranged from approximately 2 mg-to-10 mg nightly. Statistically significant reduction of nightmares was described across all three studies. Robust improvement was described in both geriatric (N=9) and active combatants (N=13), wherein mean CAPS B2 was significantly reduced, from 6.6 (SD: 1.1) to 0.9 (SD: 1.5); paired t=9.8; p <0.0001) and from 7 (SD: 0.7) to 2.9 (SD: 3; paired t=4.8; p <0.001). Pooled data from these two series15,30 revealed that nightmare response to prazosin, as defined by a ≥50% reduction in CAPS B2 occurred in 17 of 22 subjects (77%), with 11 of those 17 subjects (65%) attaining total remission (CAPS B2=0). Diminished nightmares correlated significantly with reduced sleep disturbances as measured by the CAPS D1 (r=0.74–0.63; p <0.01 to 0.05) in two series.15,29 Global clinical status was improved across the studies and was significantly correlated with improved nightmare status (r=0.94; p <0.001) in one series.15 Similar to the crossover RCT,24 nightmares rapidly re-emerged and again remitted after all-cause prazosin discontinuation and reinitiation, respectively.30 Adverse effects included “non-clinically meaningful” reduction in blood pressure, transient orthostatic lightheadedness (N=1), dizziness (N=1), nocturnal urinary incontinence in a subject with previous prostatectomy (N=1), and nausea with headache (N=1).
Retrospective Chart Review
One retrospective review32 was identified. It was positive, and was graded as Class II evidence.
It described a total of 59 subjects, divided into three groups, including 51 primary analysis participants who were exposed to prazosin and 36 who completed the full 8-week titration. Eight subjects did not take the prazosin and were used as a comparison, non-exposure group. Primary outcome measures included change in PTSD nightmares (CAPS B2 item) and post-treatment global well-being (CGI-C). The review involved an unspecified mixture of male Vietnam and Gulf War veterans. All participants had chronic DSM-IV PTSD with severe, treatment-resistant, combat-related nightmares, as evidenced by a baseline CAPS B2 score ≥5. Active substance misuse was excluded. Baseline psychotropics were continued unchanged. Mean prazosin dosing ranged from approximately 6 mg–10 mg nightly in the prazosin-exposed group (N=51) and titration completers (N=36), respectively. Statistically significant reduction of nightmares was reported in both groups. Specifically, CAPS B2 decreased from 7.1 (0.2) to 4.2 (0.3); (t=9.1; p <0.0001) in the primary analysis group and from 7 (0.2) to 3.5 (0.3); (t=9.6; p <0.0001) in the titration completer group. CAPS B2 did not significantly change in the unexposed group. Post-treatment global status was significantly (t=3.5; p <0.01) improved across the treatment group (CGI–C: 2.9 [0.1]) as compared with the unexposed group (CGI–C: 3.9 [0.1]). The most frequent adverse effects included orthostatic dizziness, (N=3), headache (N=3), and nausea (N=2). Fifteen subjects (29%) discontinued prazosin because of unspecified adverse effects.
Discussion
Our review found a positive evidence-base for the use of prazosin to manage combat-related PTSD nightmares. Seven studies, tracking a total of 210 subjects, were identified. Six of these seven studies used comparable primary outcomes and showed positive results; these included five prospective trials. There were one Class I, four Class II, and two Class III trials.
In light of published limited responsiveness of PTSD nightmares to label PTSD antidepressant interventions13,19,21 and currently available supportive empirical data,15,18,24,29,30,32 off-label prazosin augmentation has been shown to be an evidence-based pharmacological management strategy for military combat-related nightmares. This is consistent with a recent Best Practice Guideline Level A recommendation for prazosin in the management of all-cause nightmares.17 Benefit has been demonstrated across a continuum of veterans’ ages. Efficacy has been demonstrated in both garrison as well as forward-deployed, active-combat settings. Prazosin augmentation significantly reduced combat-related acute and chronic PTSD nightmares, as well as those occurring as part of an Acute Stress Disorder. Improvement may take weeks. Nightmares rapidly returned and again resolved with prazosin discontinuation and reinitiation, respectively.24,30 Nightmare improvement correlated with improved sleep15,29 and global functional status.15 Benefit may be relatively greater for military combat-trauma nightmares, as opposed to nightmares from other causes.18 Dosing strategies across available literature were similar. Consistent with FDA label guidance, prazosin was initiated at 1 mg at 30 min–60 min before bedtime to avoid potential first-dose hypotensive complications. Titration decision was typically determined via analysis of clinical response, in a setting of tolerability. The rate of titration varied from 1 mg every few days early in the trials to 2 mg–5 mg per week later in the titrations. Maximum allowable dosing ranged from 4 mg per night in a geriatric cohort to 20 mg (divided) per night. Final effective dosing ranged from approximately 2 mg to 13 mg per night. Prazosin was well-tolerated. The most common adverse effects consisted of orthostatic complications, including transient dizziness and non-statistically significant differences in blood pressure, as compared with placebo.
The only available negative study31 is also the most recent trial. It is a Class II prospective study. The impact of this negative trial is limited by the use of a dissimilar and thus difficult-to-compare primary outcome nightmare measure, as well as low frequency of nightmares at study entry, sample dilution with subthreshold PTSD, and recent “high risk for bias” designation.27 The lack of significant improvement with randomized-comparison use of an effective17 behavioral sleep intervention in this negative trial is evidence that the sample’s entry baseline low-frequency nightmare occurrence may have obscured active-treatment significant improvement.
This review has several limitations. One is the relatively small number of studies and number of subjects. This is compounded by the finding that only two of the reviewed trials24,32 enrolled only subjects with combat-related PTSD nightmares. Neither of these studies utilized a standardized quantifiable measure of combat exposure (e.g., the Combat Exposure Scale). Another limitation is the heterogeneity of the total reviewed sample in terms of duration of trauma exposure and underlying PTSD, follow-up time, varying exclusion criteria, and entry multi-axial comorbidity and associated allowable concurrent management. Although the review sample were mostly men, this is consistent with gender skewing for outside-the-wire military combat operations.
Nevertheless, given the sobering morbidity and frequency of combat-related PTSD nightmares in conjunction with the available positive evidence-base signal, this review highlights an indication for further randomized, controlled examination of prazosin, specifically in the combat-PTSD cohort. The publication of completed RCTs will ideally better characterize prazosin’s position in the combat-PTSD treatment algorithm. Interested readers are referred to clinicaltrials.gov (search term: “PTSD nightmares” and “prazosin”) to view completed, in-progress, and planned randomized, controlled trials. Indeed, future trials may establish relative prazosin responsiveness in specific combat-exposure profiles, as well as potentially instruct tailored algorithmic management strategies similar to those previously published.16
Considering the frequency, clinical course, and known bidirectional associations between all-cause nightmares and adverse medical/psychological health outcomes,7,36,37 increased specialty utilization, along with integration of prazosin into the primary prevention arena, could have a substantial impact on combat veteran well-being and health outcomes.
Footnote
Disclaimer: The opinions expressed on this document are solely those of the authors and do not represent an endorsement by or the views of the United States Air Force, the Department of Defense, or the United States Government.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
2.
Benedek DM, Ursano RJ: Posttraumatic Stress Disorder: From Phenomenology to Clinical Practice. FOCUS: The Journal of Lifelong Learning in Psychiatry 2009; VII:160–175
3.
Stern TA, Rosenbaum JF, Fava M, et al.: Massachusetts General Hospital Comprehensive Clinical Psychiatry, 1st Edition. Philadelphia, PA, Mosby Elsevier, 2008, chap 34
4.
Silver JM, McAllister TW, Yudofsky SC: Textbook of Traumatic Brain Injury, 2nd Edition. Arlington, VA, American Psychiatric Publishing, 2011, chap 12
5.
Klein S, Alexander DA: Epidemiology and presentation of post-traumatic disorders. Psychiatry 2009; 8:282–287
6.
Keane TM, Marshall AD, Taft CT: Posttraumatic stress disorder: etiology, epidemiology, and treatment outcome. Annu Rev Clin Psychol 2006; 2:161–197
7.
Pietrzak RH, Goldstein RB, Southwick SM, et al.: Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord 2011; 25:456–465
8.
Grieger TA, Cozza SJ, Ursano RJ, et al.: Posttraumatic stress disorder and depression in battle-injured soldiers. Am J Psychiatry 2006; 163:1777–1783; quiz 1860
9.
Smith TC, Ryan MAK, Wingard DL, et al.; Millennium Cohort Study Team: New onset and persistent symptoms of post-traumatic stress disorder self-reported after deployment and combat exposures: prospective population-based U.S. military cohort study. BMJ 2008; 336:366–371
10.
Andrews B, Brewin CR, Philpott R, et al.: Delayed-onset posttraumatic stress disorder: a systematic review of the evidence. Am J Psychiatry 2007; 164:1319–1326
11.
Lineberry TW, O’Connor SS: Suicide in the U.S. Army. Mayo Clin Proc 2012; 87:871–878
12.
Leard-Mann CA, Smith TC, Smith B, et al.; Millennium Cohort Study Team: Baseline self-reported functional health and vulnerability to post-traumatic stress disorder after combat deployment: prospective U.S. military cohort study. BMJ 2009; 338:b1273
13.
Lydiard RB, Hamner MH: Clinical Importance of Sleep Disturbance as a Treatment Target in PTSD. FOCUS The Journal of Lifelong Learning in Psychiatry 2009; VII:176–183
14.
Levin R, Nielsen TA: Disturbed dreaming, posttraumatic stress disorder, and affect distress: a review and neurocognitive model. Psychol Bull 2007; 133:482–528
15.
Calohan J, Peterson K, Peskind ER, et al.: Prazosin treatment of trauma nightmares and sleep disturbance in soldiers deployed in Iraq. J Trauma Stress 2010; 23:645–648
16.
Lamarche LJ, De Koninck J: Sleep disturbance in adults with posttraumatic stress disorder: a review. J Clin Psychiatry 2007; 68:1257–1270
17.
Aurora RN, Zak RS, Auerbach SH, et al.; Standards of Practice Committee; American Academy of Sleep Medicine: Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med 2010; 6:389–401
18.
Raskind MA, Peskind ER, Hoff DJ, et al.: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61:928–934
19.
Nappi CM, Drummond SP, Hall JM: Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. Neuropharmacology 2012; 62:576–585
20.
Geracioti TD, Baker DG, Ekhator NN, et al.: CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227–1230
21.
Benedek DM, Friedman MJ, Zatzick D, et al.: Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. FOCUS The Journal of Lifelong Learning in Psychiatry 2009; VII:204–213
22.
Jeffreys M, Capehart B, Friedman MJ: Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev 2012; 49:703–715
23.
Boehnlein JK, Kinzie JD: Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J Psychiatr Pract 2007; 13:72–78
24.
Raskind MA, Peskind ER, Kanter ED, et al.: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160:371–373
25.
Taylor FB, Martin P, Thompson C, et al.: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63:629–632
26.
Graham RL, Leckband SG, Endow-Eyer RA: PTSD nightmares: Prazosin and atypical antipsychotics. Current Psychiatry 2012; 11:59–62
27.
Kung S, Espinel Z, Lapid MI: Treatment of nightmares with prazosin: a systematic review. Mayo Clin Proc 2012; 87:890–900
28.
Warden DL, Gordon B, McAllister TW, et al.; Neurobehavioral Guidelines Working Group: Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma 2006; 23:1468–1501
29.
Thompson CE, Taylor FB, McFall ME, et al.: Non-nightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. J Trauma Stress 2008; 21:417–420
30.
Peskind ER, Bonner LT, Hoff DJ, et al.: Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol 2003; 16:165–171
31.
Germain A, Richardson R, Moul DE, et al.: Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in U.S. military veterans. J Psychosom Res 2012; 72:89–96
32.
Raskind MA, Thompson C, Petrie EC, et al.: Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry 2002; 63:565–568
33.
Blake DD, Weathers FW, Nagy LM, et al.: The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8:75–90
34.
Weathers FW, Ruscio AM, Keane TM: Psychometric Properties of Nine Scoring Rules for the Clinician-Administered Posttraumatic Stress Disorder Scale. Psychol Assess 1999; 11:124–133
35.
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology (publication ADM 76-338). Washington, DC, U.S. Department of Health, Education, and Welfare, 1976
36.
Pietrzak RH, Goldstein RB, Southwick SM, et al.: Personality disorders associated with full and partial posttraumatic stress disorder in the U.S. population: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Psychiatr Res 2011; 45:678–686
37.
Pietrzak RH, Goldstein RB, Southwick SM, et al.: Medical comorbidity of full and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2011; 73:697–707
Information & Authors
Information
Published In
History
Received: 15 January 2013
Revision received: 21 March 2013
Accepted: 25 March 2013
Published online: 1 January 2014
Published in print: Winter 2014
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).